Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. Clinical Medicine / 臨床醫學研究所
  4. The Studies of Epidemiology and Prognostic Markers in Epithelial Ovarian Carcinoma
 
  • Details

The Studies of Epidemiology and Prognostic Markers in Epithelial Ovarian Carcinoma

Date Issued
2016
Date
2016
Author(s)
CHIANG, Ying-Cheng
URI
http://ntur.lib.ntu.edu.tw//handle/246246/277223
Abstract
Epithelial ovarian carcinoma has the highest mortality rate among gynecologic malignancies and is an important disease in the field. Early diagnosis is difficult due to the lack of obvious initial symptoms, therefore ovarian cancer patients are usually diagnosed at advanced stage. Current treatments include debulking surgery and adjuvant chemotherapy with the regimen of platinum and paclitaxel which have a response rate of 80% for all patients and 40-60% for advanced-staged patients, but they usually relapse after initial response and ultimately die of recurrence. Chemo-resistance is an obstacle in the managements of epithelial ovarian cancer. A clinical prognostic factor reflecting the possible mechanisms and biological characteristics of oncogenesis or chemo-resistance may be helpful in the development of new therapeutic strategies. In the first study, we conducted the nationwide database analysis through Taiwan cancer registry system from 1979 to 2008 to evaluate the pattern, incidence and prognosis of epithelial ovarian carcinomas in the last three decades. The age-specific incidence rates increased especially in serous, endometrioid and clear cell carcinoma, and the age of diagnosis decreased from sixty to fifty years old in the three decades. Patients with mucinous, endometrioid, or clear cell carcinoma had better long-term survival than patients with serous carcinoma (log rank test, p<0.001). Patients with undifferentiated carcinoma or carcinosarcoma had poorer survival than those with serous carcinoma (log rank test, p<0.001). The mortality risk decreased from the period of 1996-1999 (hazard ratio [HR]: 0.90, p=0.054) to the period after 2000 (HR: 0.74, p<0.001) as compared with that from the period of 1991-1995. In the second study, we reported a new cell line, CA5171, derived from a chemotherapy-naive, epithelial ovarian carcinoma patient. The CA5171 cells presented with cobblestone morphology and a doubling time of 24 hours. Gene mutation analysis showed that the cells belonged to the type II ovarian cancer pathway with mutations of PIK3CA, PTEN and TP53. Single-nucleotide polymorphism array analysis showed no homozygous gene deletion; however, several loci of gene copy number gains were noted in chromosome 1, 2, 5, 9, 10, 12, 15, 16, 20 and X. The in vitro and in vivo experiments showed that the cells were sensitive to paclitaxel and doxorubicin, but resistant to cisplatin. The cells also presented epithelial–mesenchymal transition properties that may have been related to their invasion and migration potential. The CA5171 cells show the potential as a new cell line for studies on epithelial ovarian carcinoma. In the third study, the association of CHI3L1 expression and clinical outcomes of epithelial ovarian carcinoma patients were investigated. The expression of CHI3L1 was also higher in patients with a serous histological type, advanced stage, and chemo-resistance. Patients with high CHI3L1 expression had a shorter progression free survival (log rank test, p < 0.001) and overall survival (log rank test, p < 0.001). Patients with high CHI3L1 expression also had a high risk of recurrence (HR: 2.91, 95% CI: 1.89−4.48, p < 0.001) and death (HR: 4.03, 95% CI: 2.37−6.87, p < 0.001). In vitro studies showed that CHI3L1 up-regulated the expression of anti-apoptotic Mcl-1 protein and hampered paclitaxel-induced apoptosis of ovarian cancer cells. These results suggest that CHI3L1 shows potential as a prognostic biomarker for epithelial ovarian carcinoma. In summary, the nationwide database analysis provided the long-term epidemiological information of epithelial ovarian cancer in Taiwan. The CA5171 cell line had the potential as a new tool for studies on epithelial ovarian carcinoma. The CHI3L1 expression of ovarian cancer tissue was a potential marker for epithelial ovarian cancer patients.
Subjects
epithelial ovarian cancer
epidemiology
ovarian cancer cell line
SDGs

[SDGs]SDG3

Type
thesis
File(s)
Loading...
Thumbnail Image
Name

ntu-105-Q96421009-1.pdf

Size

23.32 KB

Format

Adobe PDF

Checksum

(MD5):77ab9f6f51f8e2aa375674c0d32b6fa4

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science